Secondly, While our in vitro and in vivo findings support the tumor-promoting roles of OLFML2A and EZH2 in TNBC progression, future large-scale clinical studies are needed to definitively correlate their expression with patient outcomes. Here, OLFML2A is linked to neoplasm.